GH Research PLC (GHRS)
NASDAQ: GHRSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
GHRS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.20B
- EPS (TTM)
- -$0.94
- Dividend yield
- None
- 52-week range
- 12.04 – 31.44
- Day range
- 17.29 – 18.32
- Volume / Avg
- 298.83K / 294.69K
- Beta
- —
- Shares outstanding
- 68.68M
52-week range
GHRS stock today
GH Research (GHRS) closed at $17.53 on Nov 20, down 5.55% (-$1.03), versus the S&P 500's 3.70% decline. At this level, GHRS sits in the middle of its 52-week range of $12.04 to $31.44: 44.2% below the high, set on Aug 7, 2026 and 45.6% above the low. GHRS is up 38.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 25.1%.
GH Research has posted a net loss over the last twelve months (EPS of -$0.94), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About GH Research
Company profileGH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Velichka Valcheva M.D., M.Sc.
- Headquarters
- Dublin
- Employees
- 73
- IPO year
- 2021
- Website
- ghres.com
Financial highlights
Full financialsGH Research reported a net loss of $48.3 million, compared with a loss of $39.0 million a year earlier. Diluted earnings per share came in at -$0.79.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-48.26M | $-38.96M | $-35.59M | $-22.46M | $-9.20M |
| EPS (diluted) | $-0.79 | $-0.75 | $-0.68 | $-0.43 | $-0.21 |
Analyst forecast
ForecastConsensus (10 analysts)
strong_buy
Avg. price target
$42.89+144.67%
- Strong buy 3
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-0.18 vs $-0.27
- Surprise
- +33.33%
GHRS news
All GHRS newsGH Research peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AMPHAmphastar Pharmaceuticals Inc. | 28.25 | +0.50% | $1.20B | vs GHRS |
| MLYSMineralys Therapeutics Inc. | 13.66 | -3.53% | $1.21B | vs GHRS |
| OCULOcular Therapeutix Inc. | 5.57 | -4.95% | $1.23B | vs GHRS |
| GENBGenerate Biomedicines Inc. | 9.54 | -8.00% | $1.23B | vs GHRS |
| SLNSilence Therapeutics Plc American Depository Share | 19.81 | 0.00% | $1.23B | vs GHRS |
| MNKDMannKind Corporation | 3.85 | -2.53% | $1.24B | vs GHRS |
| OPKOPKO Health Inc. | 1.57 | -2.48% | $1.17B | vs GHRS |
| GPCRStructure Therapeutics Inc. ADR | 16.13 | -5.78% | $1.15B | vs GHRS |
Indexes, lists and sector
GH Research stock FAQ
What is GH Research's stock price today?
GHRS last traded at $17.53 as of Nov 20, 4:00 PM EST, down 5.55% on the day. Prices are delayed at least 15 minutes.
Who is GH Research's CEO?
Dr. Velichka Valcheva M.D., M.Sc. is the chief executive officer of GH Research PLC, which has about 73 employees.
What is the GHRS 52-week high?
The 52-week high for GHRS is $31.44 and the 52-week low is $12.04. The stock is currently 44.2% below its high.